Disease · HP_0010865

Oppositional defiant disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Oppositional defiant disorder. Diseases, record HP_0010865. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0010865

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Oppositional defiant disorder; Open Targets
Open Targets ID: HP_0010865; Open Targets
Other names: ODD; Open Targets
Disease Ontology: DOID:0050856; Disease Ontology
Highest stage of its drugs: Phase 3, for 1 of its 3 drugs, from ClinicalTrials.gov; Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ATOMOXETINE	CHEMBL641	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
OXYTOCIN	CHEMBL395429	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ZIPRASIDONE HYDROCHLORIDE	CHEMBL1375743	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	1	Dopamine D2 receptor antagonist	Phase 2	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	1	Serotonin 2a (5-HT2a) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3356	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	1	Serotonin 2c (5-HT2c) receptor antagonist	Phase 2	https://conductscience.org/library/genes/3358	Drugs and targets
OXTR	Oxytocin receptor	1	Oxytocin receptor agonist	Phase 2	https://conductscience.org/library/genes/5021	Drugs and targets
SLC6A2	Sodium-dependent noradrenaline transporter	1	Norepinephrine transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6530	Drugs and targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00192023	An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).	Phase 3	139	2010-01-18	Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder	ATOMOXETINE	Its record names the disease	ClinicalTrials.gov
NCT02824627	Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders	Phase 2	58	2022-08-30	Mood Disorder, Disruptive Behavior Disorders	OXYTOCIN	Its record names the disease	ClinicalTrials.gov
NCT00191698	Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD	Phase 3	226		Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder	ATOMOXETINE	Its record names the disease	ClinicalTrials.gov
NCT00676429	Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders	Phase 2	51		Conduct Disorder, Oppositional Defiant Disorder	ZIPRASIDONE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Atomoxetine vs Placebo: serious adverse events	0 of 107	0 of 32	139	NCT00192023	Trial comparisons
Oxytocin vs Placebo: deaths from any cause	0 of 25	0 of 27	52	NCT02824627	Trial comparisons
Oxytocin vs Placebo: serious adverse events	0 of 25	0 of 27	52	NCT02824627	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34288223	DERIVED	1	PubMed
25019647	DERIVED	2	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0010865

GET https://conductscience.org/api/diseases/v1/HP_0010865/drugs

API reference For AI assistants